.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,710,140

« Back to Dashboard

Details for Patent: 5,710,140

Title: Phenyl heterocycles as COX-2 inhibitors
Abstract:The invention encompasses the novel compound of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases. ##STR1## The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.
Inventor(s): Ducharme; Yves (Montreal, CA), Gauthier; Jacques Yves (Laval, CA), Prasit; Petpiboon (Kirkland, CA), Leblanc; Yves (Kirkland, CA), Wang; Zhaoyin (Pierrefond, CA), Leger; Serge (Dollard des Ormeaux, CA), Therien; Michel (Laval, CA)
Assignee: Merck Frosst Canada, Inc. (Kirkland, CA)
Filing Date:Aug 16, 1996
Application Number:08/699,142
Claims:1. A compound of formula I ##STR216## or a pharmaceutically acceptable salt thereof wherein: X--Y--Z-- is selected from the group consisting of:

(a) --CH.sub.2 --NR.sup.3 --CH.sub.2 --,

(b) --CR.sup.5 (R.sup.5')--NR.sup.3 --C(O)--,

(c) --N.dbd.CR.sup.4 --NH--,

(d) --C(O)--NR.sup.3 --CR.sup.5 (R.sup.5')--,

(e) --NR.sup.3 --CH.dbd.CH-- provided R.sup.1 is other than --S(O).sub.2 Me, and

(f) --CH.dbd.CH--NR.sup.3 -- provided R.sup.1 is other than --S(O).sub.2 Me,

wherein side b is a double bond, and sides a and c are single bonds; and

X--Y--Z-- is .dbd.CH--NR.sup.3 --CH.dbd.,

wherein sides a and c are double bonds and side b is a single bond;

R.sup.1 is selected from the group consisting of

(a) S(O).sub.2 CH.sub.3,

(b) S(O).sub.2 NH.sub.2,

(c) S(O).sub.2 NHC(O)CF.sub.3,

(d) S(O)(NH)CH.sub.3,

(e) S(O)(NH)NH.sub.2,

(f) S(O)(NH)NHC(O)CF.sub.3,

(g) P(O)(CH.sub.3)OH, and

(h) P(O)(CH.sub.3)NH.sub.2,

R.sup.2 is selected from the group consisting of

(a) C.sub.1-6 alkyl,

(b) C.sub.3, C.sub.4, C.sub.5, C.sub.6, and C.sub.7, cycloalkyl,

(c) mono-, di- or tri-substituted phenyl wherein the substituent is selected from the group consisting of

(1) hydrogen,

(2) halo,

(3) C.sub.1-6 alkoxy,

(4) C.sub.1-6 alkylthio,

(5) CN,

(6) CF.sub.3,

(7) C.sub.1-6 alkyl,

(8) N.sub.3,

(9) --CO.sub.2 H,

(10) --CO.sub.2 --C.sub.1-4 alkyl,

(11) --C(R.sup.5)(R.sup.6)--OH,

(12) --C(R.sup.5)(R.sup.6)--O--C.sub.1-4 alkyl, and

(13) --C.sub.1-6 alkyl-CO.sub.2 --R.sup.5 ; and

(d) mono-, di- or tri-substituted heteroaryl wherein the heteroaryl is a monocyclic aromatic ring of 5 atoms, said ring having one hetero atom which is S, O, or N, and optionally 1, 2, or 3 additional N atoms; or

the heteroaryl is a monocyclic ring of 6 atoms, said ring having one hetero atom which is N, and optionally 1, 2 or 3 additional N atoms; said substituents are selected from the group consisting of

(1) halo, including fluoro, chloro, bromo and iodo,

(2) C.sub.1-6 alkyl,

(3) C.sub.1-6 alkoxy,

(4) C.sub.1-6 alkylthio,

(5) CN,

(6) CF.sub.3,

(7) N.sub.3,

(8) --C(R.sup.5)(R.sup.6)--OH, and

(9) --C(R.sup.5)(R.sup.6)--O--C.sub.1-4 alkyl;

R.sup.3 is selected from the group consisting of

(a) hydrogen,

(b) CF.sub.3,

(c) CN,

(d) C.sub.1-6 alkyl,

(e) hydroxy C.sub.1-6 alkyl, and

(f) --C(O)--C.sub.1-6 alkyl,

(g) optionally substituted

(1) --C.sub.1-5 alkyl-Q,

(2) --C.sub.1-3 alkyl-O--C.sub.1-3 alkyl-Q,

(3) --C.sub.1-3 alkyl-S--C.sub.1-3 alkyl-Q,

(4) --C.sub.1-5 alkyl-O--Q, or

(5)--C.sub.1-5 alkyl-S--Q,

wherein the substituent resides on the alkyl and the substituent is C.sub.1-3 alkyl; and

(h) --Q;

R.sup.4 is selected from the group consisting of

(a) hydrogen,

(b) CF.sub.3,

(c) CN,

(d) C.sub.1-6 alkyl,

(e) --Q,

(f) --O--Q;

(g) --S--Q, and

(h) optionally substituted

(1) --C.sub.1-5 alkyl-Q,

(2)--O--C.sub.1-5 alkyl-Q,

(3)--S--C.sub.1-5 alkyl-Q,

(4) --C.sub.1-3 alkyl-O-C.sub.13 alkyl-Q,

(5) --C.sub.1-3 alkyl-S--C.sub.1-3 alkyl-Q,

(6) --C.sub.1-5 alkyl-O--Q, or

(7) --C.sub.1-5 alkyl-S--Q,

wherein the substituent resides on the alkyl and the substituent is C .sub.1-3 alkyl, and

R.sup.5 and R.sup.6, R.sup.7 and R.sup.8 are each independently selected from the group consisting of

(a) hydrogen,

(b) C.sub.1-6 alkyl,

or R.sup.5 and R.sup.6 or R.sup.7 and R.sup.8 together with the carbon to which they are attached form a monocyclic saturated carbon ring of 3, 4, 5, 6 or 7 atoms;

Q is CO.sub.2 H, CO.sub.2 -C.sub.1-4 alkyl, tetrazolyl-5-yl, C(R.sup.7)(R.sup.8)(OH), or C(R.sup.7)(R.sup.8)(O--C.sub.1-4 alkyl).

2. A compound according to claim 1 wherein

R.sup.1 is selected from the group consisting of

(a) S(O).sub.2 CH.sub.3,

(b) S(O).sub.2 NH.sub.2,

(c) S(O).sub.2 NHC(O)CF.sub.3,

(d) S(O)NHCH.sub.3,

(e) S(O)NHNH.sub.2, and (f) S(O)NHNHC(O)CF.sub.3 ;

R.sup.2 is selected from the group consisting of

(a) C.sub.1-4 alkyl,

(b) C.sub.3, C.sub.4, C.sub.5, C.sub.6, and C.sub.7, cycloalkyl,

(c) mono- or di-substituted phenyl wherein the substituent is selected from the group consisting of

(1) fluoro, chloro, and bromo,

(2) C.sub.1-4 alkoxy,

(3) C.sub.1-4 alkylthio,

(4) CN,

(5) CF.sub.3,

(6) C.sub.1-4 alkyl,

(7) N.sub.3,

(8) --CO.sub.2 H,

(9) --CO.sub.2 --C.sub.1-3 alkyl,

(10) --C(R.sup.5)(R.sup.6)--OH, and

(11) --C(R.sup.5)(R.sup.6)--O--C.sub.1-3 alkyl, and

(d) mono- or di-substituted heteroaryl selected from the group consisting of

(1) furanyl,

(2) diazinyl, triazinyl and tetrazinyl,

(3) imidazolyl,

(4) isooxazolyl,

(5) isothiazolyl,

(6) oxadiazolyl,

(7) oxazolyl,

(8) pyrazolyl,

(9) pyrrolyl,

(10) thiadiazolyl,

(11) thiazolyl,

(12) thienyl,

(13) triazolyl, and

(14) tetrazolyl,

wherein said substituents are selected from the group consisting of

(a) hydrogen,

(b) fluoro, chloro, bromo,

(c) C.sub.1-4 alkoxy,

(d) C.sub.1-4 alkylthio,

(e) CN,

(5) CF.sub.3,

(6) C.sub.1-4 alkyl,

(7) N.sub.3,

(8) --C(R.sup.5)(R.sup.6)--OH, and

(9) --C(R.sup.5)(R.sup.6)--O--C.sub.1-4 alkyl.

3. A compound according to claim 2 wherein

R.sup.2 is selected from the group consisting of

(a) cyclohexyl, and

(b) mono- or di-substituted phenyl, wherein the substituents are selected from the group consisting of

(1) halo,

(2) C.sub.1-4 alkoxy,

(3) C.sub.1-4 alkylthio,

(4) CN,

(5) CF.sub.3,

(6) C.sub.1-4 alkyl,

(7) N.sub.3, and

(8) --C(R.sup.5)(R.sup.6)--OH;

R.sup.3 is selected from the group consisting of

(a) hydrogen,

(b) CF.sub.3,

(c) C.sub.1-3 alkyl and hydroxy C.sub.1-3 alkyl, and

(d) CN,

R.sup.4 is selected from the group consisting of

(a) hydrogen,

(b) CF.sub.3,

(c) C.sub.1-3 alkyl,

(d) CN,

(e) chloro and fluoro; and

R.sup.5 ', R.sup.5', R.sup.6, are each independently selected from the group consisting of

(a) hydrogen,

(b) methyl or ethyl,

or R.sup.5 and R.sup.6 together with the carbon to which they are attached form a saturated carbon ring of 4, 5 or 6 atoms.

4. A compound according to claim 3 wherein

X--Y--Z-- is selected from the group consisting of:

(a) --CH.sub.2 --NR.sup.3 --CH.sub.2 --,

(b) --CH.sup.2 --NR.sup.3 --C(O)--,

(c) --N.dbd.CR.sup.4 --NH--,

(d) --NR.sup.3 --CH.dbd.CH-- provided R.sup.1 is other than --S(O).sub.2 Me,

(e) --CH.dbd.CH--NR.sup.3 -- provided R.sup.1 is other than --S(O).sub.2 Me, and

(f) .dbd.CH--NR.sup.3 --CH.dbd.,

R.sup.1 is selected from the group consisting of

(a) S(O).sub.2 CH.sub.3,

(b) S(O).sub.2 NH.sub.2,

(c) S(O)NHCH.sub.3, and

(d) S(O)NHNH.sub.2 ;

R.sup.2 is selected from the group consisting of

mono or di-substituted phenyl wherein the substituents are selected from the group consisting of

(1) halo, selected from the group consisting of fluoro, chloro and bromo,

(2) C.sub.1-3 alkoxy,

(3) C.sub.1-3 alkylthio,

(4) CN, and

(5) C.sub.1-3 alkyl; and

R.sup.3 is selected from the group consisting of

(a) hydrogen,

(b) CF.sub.3,

(c) C.sub.1-3 alkyl and hydroxy C.sub.1-3 alkyl.

5. A compound according to claim 4 wherein

R.sup.1 is selected from the group consisting of

(a) S(O).sub.2 CH.sub.3,

(b) S(O).sub.2 NH.sub.2,

(c) S(O)NHCH.sub.3, and

(d) S(O)NHNH.sub.2 ;

R.sup.2 is

mono or di-substituted phenyl wherein the substituents are selected from the group consisting of

(1) halo, selected from the group consisting of fluoro, chloro and bromo,

(2) methoxy, and

(3) methyl.

6. A compound according to claim 5 wherein

R.sup.1 is selected from the group consisting of

(a) S(O).sub.2 CH.sub.3, and

(b) S(O).sub.2 NH.sub.2,

R.sup.2 is

mono or di-substituted phenyl wherein the substituents are selected from the group consisting of

(1) halo, selected from the group consisting of fluoro, chloro and bromo.

7. A compound according to claim 2 wherein

R.sup.2 is a mono- or di-substituted heteroaryl wherein heteroaryl is selected from the group consisting of

(1) furanyl,

(2) diazinyl, triazinyl, tetrazinyl,

(3) imidazolyl,

(4) isooxazolyl,

(5) isothiazolyl,

(6) oxadiazolyl,

(7) oxazolyl,

(8) pyrazolyl,

(9) pyrrolyl,

(10) thiadiazolyl,

(11) thiazolyl,

(12) thienyl,,

(13) triazolyl, and ,

(14) tetrazolyl,

wherein the substituents are selected from the group consisting of

(a) hydrogen,

(b) fluoro or chloro,

(c) C.sub.1-3 alkoxy,

(d) C.sub.1-6 alkyl thio,

(e) CN,

(5) CF.sub.3,

(6) C.sub.1-3 alkyl,

(7) --C(R.sup.5)(R.sup.6)--OH; and

(8) --C(R.sup.5)(R.sup.6)--O--C.sub.1-4 alkyl.

8. A compound according to claim 7 wherein

R.sup.2 is a mono- or di-substituted heteroaryl wherein heteroaryl is selected from the group consisting of

(1) 2-furanyl,

(2) 3-furanyl,

(3) 2-thienyl,

(4) 3-thienyl,

(5) 3-isoxazolyl,

(6) 4-isoxazolyl,

(7) 5-isoxazolyl,

(8) 3-isothiazolyl,

(9) 4-isothiazolyl,

(10) 5-isothiazolyl,

(11) 2-oxazolyl,

(12) 4-oxazolyl,

(13) 5-oxazolyl,

(14) 2-thiazolyl,

(15) 4-thiazolyl,

(16) 5-thiazolyl,

(17) 1,2,3-thiadiazol-4-yl,

(18) 1,2,3-thiadiazol-5-yl,

(19) 1,2,4-thiadiazol-3-yl,

(20) 1,2,4-thiadiazol-5-yl,

(21) 1,3,4-thiadiazol-2-yl,

(22) 1,2,5-thiadiazol-3-yl,

(23) 1,2,3-oxadiazol-4-yl,

(24) 1,2,3-oxadiazol-5-yl,

(25) 1,2,4-oxadiazol-3-yl,

(26) 1,2,4-oxadiazol-5-yl,

(27) 1,3,4-oxadiazol-2-yl,

(28) 1,2,5-oxadiazol-3-yl,

(29) pyrazol-4-yl,

(30) pyrazol-5-yl,

(31) 1,2,3-triadiazol-4-yl,

(32) 1,2,3-triadiazol-5-yl,

(33) 1,2,4-triadiazol-3-yl,

(34) 1,2,4-triadiazol-5-yl,

(35) 1,2-diazinyl,

(36) 1,3-diazinyl,

(37) 1,4-diazinyl,

(38) 1,2,3,4-tetrazin-5-yl,

(39) 1,2,4,5-tetrazin-4-yl,

(40) 1,3,4,5-tetrazin-2-yl , and

(41) 1,2,3,5-tetrazin-4-yl.

9. A compound according to claim 8 wherein the heteroaryl is selected from the group consisting of

(1) 3-isoxazolyl,

(2) 4-isoxazolyl,

(3) 5-isoxazolyl,

(4) 3-isothiazolyl,

(5) 4-isothiazolyl,

(6) 5-isothiazolyl,

(7) 2-oxazolyl,

(8) 4-oxazolyl,

(9) 5-oxazolyl,

(10) 2-thiazolyl,

(11) 4-thiazolyl,

(12) 5-thiazolyl,

(13) 1,2,3-thiadiazol-4-yl,

(14) 1,2,3-thiadiazol-5-yl,

(15) 1,2,4-thiadiazol-3-yl,

(16) 1,2,4-thiadiazol-5-yl,

(17) 1,3,4-thiadiazol-2-yl,

(18) 1,2,5-thiadiazol-3-yl,

(19) 1,2,3-oxadiazol-4-yl,

(20) 1,2,3-oxadiazol-5-yl,

(21) 1,2,4-oxadiazol-3-yl,

(22) 1,2,4-oxadiazol-5-yl,

(23) 1,3,4-oxadiazol-2-yl,

(24) 1,2,5-oxadiazol-3-yl,

(25) 1,2-diazinyl,

(26) 1,3-diazinyl, and

(27) 1,4-diazinyl.

10. A compound according to claim 9 wherein the heteroaryl is selected from the group consisting of

(1) 3-isothiazolyl,

(2) 4-isothiazolyl,

(3) 5-isothiazolyl,

(4) 2-oxazolyl,

(5) 4-oxazolyl,

(6) 5-oxazolyl,

(7) 2-thiazolyl,

(8) 4-thiazolyl,

(9) 5-thiazolyl,

(10) 1,2-diazinyl,

(11) 1,3-diazinyl, and

(12) 1,4-diazinyl,

wherein the substituents are selected from the group consisting of

(1) hydrogen,

(2) fluoro or chloro,

(3) .sub.1-3 alkoxy,

(4) C.sub.1-3 alkylthio,

(5) CN,

(6) C.sub.1-3 alkyl, and

(7) --C(R.sup.5)(R.sup.6)--OH,

wherein R5 and R6 are each independently hydrogen, methyl or ethyl.

11. A compound according to claim 10 wherein

R.sup.1 is selected from the group consisting of

(a) S(O).sub.2 CH.sub.3,

(b) S(O).sub.2 NH.sub.2,

(c) S(O)NHCH.sub.3, and

(d) S(O)NHNH.sub.2, and

R.sup.3 is selected from the group consisting of

(a) hydrogen,

(b) CF.sub.3,

(c) C.sub.1-3 alkyl and hydroxy C.sub.1-3 alkyl, and

(d) CN.

12. A compound according to claim 11 wherein the hetereooaryl is selected from the group consisting of

(1) 3-isothiazolyl,

(2) 4-isothiazolyl,

(3) 5-isothiazolyl,

(4) 2-oxazolyl,

(5) 4-oxazolyl,

(6) 5-oxazolyl,

(7) 2-thiazolyl,

(8) 4-thiazolyl,

(9) 5-thiazolyl,

(10) 1,2-diazinyl,

(11) 1,3-diazinyl, and

(12) 1,4-diazinyl, and

wherein the substituents are selected from the group consisting of

(1) hydrogen,

(2) fluoro or chloro,

(3) methoxy,

(4) methylthio,

(5) CF.sub.3,

(6) methyl.

13. A pharmaceutical composition for treating an inflammatory disease susceptable to treatment with a non-steroidal anti-inflammatory agent comprising:

a non-toxic therapeutically effective amount of a compound according to claim 1 and a pharmaceutically acceptable carder.

14. A pharmaceutical composition for treating cyclooxygenase mediated diseases advantageously treated by an active agent that selectively inhibits COX-2 in preference to COX-1 comprising:

a non-toxic therapeutically effective amount of a compound according to claim 1 and a pharmaceutically acceptable carrier.

15. A method of treating an inflammatory disease susceptable to treatment with a non-steroidal anti-inflammatory agent comprising: administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound according to claim 1 and a pharmaceutically acceptable carder.

16. A method of treating cyclooxygenase mediated diseases advantageously treated by an active agent that selectively inhibits COX-2 in preference to COX-1 comprising:

administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound according to claim 1.

17. A compound according to claim 1 selected from the group consisting of: ##STR217## or a pharmaceutically acceptable salt thereof.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc